Namwiwat Medical PCL (BKK:NAM) ROCE %: 3.88% (As of Mar. 2026)


BKK:NAM Namwiwat Medical Corp PCL BKK:NAM
40 GF Score
Price ฿3.40
GF Value ฿6.04
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Namwiwat Medical PCL ROCE %?

Namwiwat Medical PCL BKK:NAM -1.73% 40 ROCE % is 3.88% as of Mar. 2026. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Namwiwat Medical PCL's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.88%.

Namwiwat Medical PCL  (BKK:NAM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Namwiwat Medical PCL ROCE % Related Terms

Namwiwat Medical PCL ROCE % Historical Data

* Premium members only.

The historical data trend for Namwiwat Medical PCL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Namwiwat Medical PCL ROCE % Chart

Namwiwat Medical PCL Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 43.91 23.97 15.46 11.40 7.67

Namwiwat Medical PCL Quarterly Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.28 2.97 7.16 5.71 3.88
BKK:NAM
40GF Score
Namwiwat Medical Corp PCL BKK:NAM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Namwiwat Medical PCL ROCE % Calculation

Namwiwat Medical PCL's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=172.514/( ( (2709.052 - 506.992) + (3051.973 - 755.549) )/ 2 )
=172.514/( (2202.06+2296.424)/ 2 )
=172.514/2249.242
=7.67 %

Namwiwat Medical PCL's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=89.196/( ( (3051.973 - 755.549) + (2885.694 - 585.836) )/ 2 )
=89.196/( ( 2296.424 + 2299.858 )/ 2 )
=89.196/2298.141
=3.88 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.88% mean?
Namwiwat Medical PCL (BKK:NAM) has a ROCE % of 3.88% as of Mar. 2026.
Is Namwiwat Medical PCL's ROCE % too high?
Namwiwat Medical PCL's current ROCE % is 3.88%. The Medical Devices & Instruments industry median ROCE % is 2.19. Namwiwat Medical PCL's value of 3.88% is 77.2% above this industry median. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's ROCE % compare to ABT and SYK?
Namwiwat Medical PCL's ROCE % of 3.88% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.19. Namwiwat Medical PCL's value of 3.88% is 77.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.19, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current ROCE % of 3.88% is 77.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current ROCE % is 3.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current ROCE % is 3.88% and 77.2% above the Medical Devices & Instruments industry median of 2.19. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current ROCE % is 3.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?

Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued. The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04. GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.

Key valuation signals for BKK:NAM:

  • ROCE %: 3.88%
  • GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
  • GF Score™: 40/100 with 5 warning signs
  • Industry Position: 77.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Namwiwat Medical PCL Business Description

Address 999/3-5 Moo 9 Prachauthit - Ku Sang Road, Nai Khlong Bang Pla Kot, Phra Samut Chedi, Samut Prakan, THA, 10290
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score

Get the complete analysis for BKK:NAM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.40
Price
฿6.04
GF Value